Excelling injectables therapy
Injectables practices today encompass three main phases of the aging process - delaying the appearance of aging signs in younger patients, treating first signs of aging, and treating existing aging signs to allow graceful aging. Aging is caused by intrinsic and extrinsic factors across multiple layers of the skin. Treating these signs inside-out is the way to achieve satisfactory results. The synergistic value obtained by combining energy-based treatments with injectables administration is a well-known industry secret, making combined therapies the next innovation front.
Sisram’s injectables operation offers skin boosters, dermal facial fillers and soon – a new generation of toxins and fat dissolving injectables. The synergy between Alma’s cumulative knowledge and practice treating multiple medical and clinical indications via energy-based devices, and Sisram’s injectables operation, provides our professional customers with a unique medical effective portfolio, bringing real value to their patients and improving consumer satisfaction. Sisram is continuously expanding its injectables offering, focusing on the fast-growing Asia Pacific geography that is marked as THE future leading market.
Profhilo, a breakthrough skin treatment injectable, has introduced a new category of bio remodelling to the injectables industry. Developed by IBSA, a multinational pharmaceutical corporation, owner of 65 exclusive registered patents worldwide, Profhilo is composed of a stabilized Hyaluronic Acid, designed to remodel multi-layer skin tissue, treating the source of aging as well as the aging symptoms.
Aliaxin products line, by IBSA, is a non-invasive, innovative treatment for natural contouring, lifting and hydration. Aliaxin dermal fillers contain ultrapure hyaluronic acid, seamlessly integrating with the skin tissue and providing a complete array of treatment solutions covering 12 different facial areas.
A new, premium, long-lasting neuromodulator product, DaxibotulinumtoxinA for Injection, aiming to upscale toxins injectables therapy. DaxibotulinumtoxinA, part of Revance Aesthetics development portfolio, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. RZL-012 is an injectable treatment for aesthetics indications and a variety of fat disorders, developed by Raziel Therapeutics, a clinical-stage pharmaceutical company. A single treatment session of RZL-012 injection into subcutaneous fat, results in significant and sustained reduction in fat volume.
For more information, please contact us:[email protected]